Lipocine Inc.   Report issue

For profit Phase 3
Founded: Salt Lake City UT United States (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2014
NCT02081300
First Marketed Drug
2020
testosterone (delatestryl)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Chief Medical Director, Lipocine, Inc. | Lipocine Inc. | LIPOCINE INC

Active Ingredients

Marketed Drugs (1)

testosterone (delatestryl) (2020)

Drugs in Phase 3 Trials (1)

testosterone (delatestryl) (7 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Eunuchism (Phase 3)

Fatty Liver (Phase 2)

Hypogonadism (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 1